Lupeol

Lupeol is a pentacyclic triterpenoid compound found in various fruits and medicinal plants that demonstrates significant anti-cancer properties. This bioactive compound works by inducing apoptosis and inhibiting tumor cell proliferation through multiple molecular pathways.

Origin & History

Lupeol is a pentacyclic triterpenoid (also known as fagarsterol) found naturally in various plants including white cabbage, green pepper, strawberry, olive, mangoes, grapes, and medicinal plants. It is typically extracted from fruits, vegetables, and herbs through methods like solvent extraction or isolation from plant lipids.

Historical & Cultural Context

While lupeol is described as a dietary compound from common fruits and vegetables with reported beneficial properties, the sources provide no specific traditional medicine context or historical uses. Animal model efficacy for various conditions may imply a basis in traditional plant uses, but no traditional systems or durations are detailed.

Health Benefits

• May help prevent tumor progression and metastasis based on veterinary trial in dogs with oral melanoma (n=20, PMC4251128) • Shows anti-tumor effects in preclinical models of pancreatic, prostate, head/neck, colorectal, and hepatocellular cancers through growth inhibition and apoptosis induction • Demonstrates anti-inflammatory and antioxidant effects in animal models • May provide cardioprotective, hepatoprotective, and neuroprotective benefits based on animal studies • Potentially helps overcome chemotherapy resistance by inhibiting ABCG2 in colorectal cancer cells (preclinical evidence only)

How It Works

Lupeol exerts its anti-cancer effects by modulating key signaling pathways including NF-κB, PI3K/Akt, and MAPK cascades, leading to reduced inflammation and tumor progression. The compound induces apoptosis through activation of caspase-3 and caspase-9 while downregulating anti-apoptotic proteins like Bcl-2. Additionally, lupeol inhibits angiogenesis by suppressing VEGF expression and blocks metastasis through reduced matrix metalloproteinase activity.

Scientific Research

Human clinical evidence is absent; the only clinical trial was conducted in dogs with oral malignant melanoma (n=20, PMC4251128) using 10 mg/kg subcutaneous lupeol, showing prevention of local tumor progression and distant metastasis. Preclinical studies in mouse xenografts demonstrate anti-tumor effects, but no human RCTs or meta-analyses exist.

Clinical Summary

Clinical evidence for lupeol is limited, with the most significant study being a veterinary trial in 20 dogs with oral melanoma showing potential anti-metastatic effects. Most research consists of preclinical studies demonstrating anti-tumor activity against pancreatic, prostate, head/neck, colorectal, and hepatocellular cancers through growth inhibition and apoptosis induction. While laboratory results are promising across multiple cancer cell lines, human clinical trials are lacking. The evidence suggests potential therapeutic value but requires substantial human research to establish clinical efficacy and optimal dosing protocols.

Nutritional Profile

Lupeol is a pentacyclic triterpenoid compound (molecular formula C30H50O, molecular weight 426.72 g/mol), not a conventional food ingredient with macronutrient or micronutrient content. It is a pure bioactive phytochemical, not a source of protein, carbohydrates, fat, vitamins, or minerals in any meaningful dietary sense. Naturally occurring concentrations vary by source: found at approximately 0.1–2% dry weight in mango (Mangifera indica) peel and pulp, present in olive oil at trace levels, found in fig (Ficus species) latex and bark at up to 3–5% of extractable triterpene fraction, and detectable in aloe vera, grape skin, and various medicinal plants. As a pure compound, it is typically studied and supplemented in doses ranging from 25–200 mg/kg body weight in preclinical animal models. Human bioavailability data is limited; as a lipophilic triterpene, oral absorption is expected to be low without lipid-based delivery systems, with enhanced absorption reported when formulated in nanoparticle or liposomal carriers. It undergoes hepatic metabolism and is primarily excreted via bile. No caloric value, fiber content, or micronutrient contribution is attributed to lupeol as an isolated compound. Its biological activity is attributed entirely to its triterpenoid scaffold, which interacts with signaling pathways including STAT3, NF-κB, and PI3K/Akt.

Preparation & Dosage

No clinically studied human dosages have been established. In veterinary use, 10 mg/kg subcutaneous was used starting twice weekly post-surgery, tapering to monthly. Animal studies have used 40-200 mg/kg orally with no toxicity observed. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

TRAIL, cisplatin, oxaliplatin, other plant triterpenoids, antioxidant compounds

Safety & Interactions

Safety data for lupeol supplementation in humans is extremely limited due to lack of clinical trials. Based on traditional use of lupeol-containing plants, the compound appears generally well-tolerated, but specific dosage thresholds and long-term safety profiles remain unknown. No documented drug interactions exist, though theoretical concerns include potential enhancement of chemotherapy effects or interference with cancer treatments. Pregnant and breastfeeding women should avoid lupeol supplements due to insufficient safety data, and individuals with existing medical conditions should consult healthcare providers before use.